Pulmicort’s revenue trends
In 3Q17, AstraZeneca’s (AZN) Pulmicort generated revenues of $242.0 million, which reflected ~8.0% growth on a YoY basis and 7.0% growth quarter-over-quarter. Pulmicort generated 9M17 revenues of $805.0 million, which reflected ~4.0% growth on a YoY basis.
Pulmicort is used for the treatment of asthma attacks in patients aged above six years. In emerging markets, Pulmicort reported 9M17 revenues of $571.0 million, which reflected ~14.0% growth YoY.
The volume growth in China, the Middle East, and North Africa was primarily attributed to the revenue growth of Pulmicort. The revenues from emerging markets contributed to ~71% of Pulmicort’s net revenues.
Daliresp/Daxas: Revenue trends
Daliresp is used for the treatment of adults with COPD (chronic obstructive pulmonary disease). In 3Q17, Daliresp/Daxas generated revenues of $53.0 million, which represents ~26.0% growth on a YoY basis and 10.0% growth on a quarter-over-quarter basis.
Daliresp/Daxas reported 9M17 revenues of $145.0 million, which reflects ~28.0% growth on a YoY basis.
In 9M17 in the US market, Daliresp generated revenues of $124.0 million, which reflected ~86.0% growth on a YoY basis. Favorable pricing and increasing use of Daliresp primary affected the drug’s revenue growth. In 9M17 outside the US market, Daliresp reported revenues of $21.0 million, reflecting 75.0% growth YoY.
Tudorza’s revenue trends
In 3Q17, Tudorza generated revenues of $37.0 million, which reflected an ~21.0% decline on a YoY basis and 9.0% growth on a quarter-over-quarter basis.
Tudorza reported 9M17 revenues of $108.0 million, which is an ~19.0% decline on a YoY basis. In 9M17 in the US market, Tudorza reported revenues of $47.0 million, which reflected ~23.0% growth YoY.
Tudorza (aclidinium bromide) is used for the long-term maintenance treatment of individuals with COPD. In the marketplace, Tudorza competes with Boehringer Ingelheim’s Atrovent and Novartis’s (NVS) Ultibro Breezhaler.
AstraZeneca comprises ~0.30% of the Vanguard FTSE Europe ETF (VGK) total portfolio holdings.